Real-world evidence of first-line pembrolizumab plus chemotherapy in metastatic non-squamous NSCLC: A single-centre experience

被引：0
|
作者：
Bose, Subhadeep [1 ]
Khaja, Mujtaba Syed [1 ]
Siva, Asha [1 ]
Wilson, Paula [1 ]
Grist, Helen [1 ]
Murukesh, Nishanth [1 ]
机构：
[1] Worcestershire Acute Hosp NHS Trust, Worcester, W Midlands, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21091
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Real-world use of first-line pembrolizumab plus platinum plus taxane combination regimens in recurrent / metastatic head and neck squamous cell carcinoma
    Black, Christopher M.
    Zheng, Dandan
    Hair, Gleicy M.
    Ai, Lei
    Wang, Liya
    Goto, Daisuke
    Lerman, Nati
    Bidadi, Behzad
    Hanna, Glenn J.
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [22] Response to the Letter re: Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
    Leonetti, Alessandro
    Perrone, Fabiana
    Puntoni, Matteo
    Maglietta, Giuseppe
    Caminiti, Caterina
    Tiseo, Marcello
    EUROPEAN JOURNAL OF CANCER, 2024, 212
  • [23] ORIENT-11: Sintilimab plus Pemetrexed plus Platinum as First-Line Therapy for Locally Advanced or Metastatic Non-Squamous NSCLC
    Zhang, L.
    Yang, Y.
    Wang, Z.
    Fang, J.
    Yu, Q.
    Han, B.
    Cang, S.
    Chen, G.
    Mei, X.
    Yang, Z.
    Ma, R.
    Bi, M.
    Ren, X.
    Zhou, J.
    Li, B.
    Xu, W.
    Ji, Y.
    Peng, B.
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (10) : E41 - E41
  • [24] First-Line Pembrolizumab-Combination Therapy for Advanced Squamous NSCLC: Real-World Outcomes at US Oncology Practices
    Liu, S.
    Rai, P.
    Wang, D.
    Hu, X.
    Schwarzenberger, P.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S383 - S384
  • [25] Efficacy of Checkpoint Inhibitors in Combination with Chemotherapy for First-Line Treatment of Advanced Non-Squamous NSCLC
    Thein, K.
    Jahan, N.
    Sultan, A.
    Swarup, S.
    Tun, A.
    Yendala, R.
    Ball, S.
    Hlaing, P.
    Htut, T.
    Rehman, S.
    D'Cunha, N.
    Hardwicke, F.
    Tijani, L.
    Awasthi, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S472 - S473
  • [26] FIRST-LINE COMBINATION THERAPIES FOR ADVANCED RENAL CELL CARCINOMA (ARCC): AN ITALIAN SINGLE-CENTRE REAL-WORLD CLINICAL EXPERIENCE
    Mercinelli, Chiara
    Massaro, Giulia
    Bonato, Adele
    Nuzzo, Amedeo
    Manacorda, Simona
    Sammarco, Enrico
    Manfredi, Fiorella
    Ferrari, Marco
    Salfi, Alessia
    Serafin, Debora
    Zatteri, Luca
    Antonuzzo, Andrea
    Galli, Luca
    ANTICANCER RESEARCH, 2022, 42 (10) : 5144 - 5145
  • [27] First-line Atezolizumab plus Bevacizumab for Metastatic High-Intermediate TMB in Non-squamous NSCLC. The TELMA Study
    Provencio-pulla, M.
    Ortega, A. L.
    Coves, J.
    Franco, F.
    Marse, R.
    Domine, M.
    Guirado, M.
    Carcereny, E.
    Fernandez, N.
    Martinez, E.
    Blanco, R.
    Leon, L.
    Sanchez, J. M.
    Sullivan, I.
    Cobo, M.
    Sanchez, A.
    Massuti, B.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S123 - S124
  • [28] REAL-WORLD USE OF PEMBROLIZUMAB COMBINATION REGIMENS IN FIRST-LINE RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
    Black, Christopher
    Wang, Liya
    Ramakrishnan, Karthik
    Goto, Daisuke
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A832 - A832
  • [29] Real World Experience of First Line Pembrolizumab for Non-Small Cell Lung Cancer (NSCLC) at a Tertiary Centre
    Fletcher, J.
    Mullally, W. J.
    Berman, C.
    Ladwa, R.
    Xu, W.
    O'Byrne, K.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S628 - S629
  • [30] A single centre experience of first-line pembrolizumab in stage IV non-small-cell lung cancer (NSCLC)
    Denslow, R.
    Yarde, A.
    Brunner, C.
    Walther, J.
    Botten, J.
    Jankowska, P.
    LUNG CANCER, 2019, 127 : S35 - S35
12345